Domestic pharma maker Mankind Pharma today announced their partnership with Innovent Biologics to exclusively license and sell sintilimab , an advanced PD-1 immunotherapy , in the Indian market. ET Year-end Special Reads Corporate Kalesh: Top family disputes of India Inc in 2024 The world of business lost these eminent people in 2024 Fast, faster, fastest: How 2024 put more speed into your shopping “This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region,” the company said in a statement. According to The National Cancer Registry Programme Cancer has become a major health concern in India, with its burden projected to reach 29.
8 million DALYs by 2025. Sintilimab, marketed as TYVYT (sintilimab injection) in China, is a high-quality PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly. Its mechanism of blocking the PD-1/PD-L1 pathway reactivates T-cells, enhancing the body's natural ability to target and eliminate cancer cells.
“The drug has demonstrated remarkable efficacy and favorable safety across multiple major cancer types with eight approved indications in China, including non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin's lymphoma. TYVYT (sintilimab injection), is one of the top therapy choices in immunotherapy, has already benefited millions of cancer patients since its .
